Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia

被引：56

作者：

Khosrovaneh, A ^{[1
]}

Riederer, K ^{[1
]}

Saeed, S ^{[1
]}

Tabriz, MS ^{[1
]}

Shah, AR ^{[1
]}

Hanna, MM ^{[1
]}

Sharma, M ^{[1
]}

Johnson, LB ^{[1
]}

Fakih, MG ^{[1
]}

Khatib, R ^{[1
]}

机构：

[1] St John Hosp & Med Ctr, Dept Med, Infect Dis Sect, Detroit, MI 48236 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 38卷 / 09期

关键词：

D O I：

10.1086/383036

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vancomycin susceptibility was checked in isolates from initial and final blood samples obtained from 22 patients with persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. The minimum inhibitory concentration of vancomycin was determined using Etest and found to have increased in 2 pairs of isolates, and results of screening in 4 mug vancomycin and a modified population analysis profile suggested heteroresistance in 3 isolates (13.6%). Heteroresistance is not a common cause of persistent or recurrent bacteremia.

引用

页码：1328 / 1330

页数：3

共 12 条

[1] Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus [J].

Aucken, HM ;

Warner, M ;

Ganner, M ;

Johnson, AP ;

Richardson, JF ;

Cookson, BD ;

Livermore, DM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :639-640

[2] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].

Hiramatsu, K ;

Hanaki, H ;

Ino, T ;

Yabuta, K ;

Oguri, T ;

Tenover, FC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136

[3] Glycopeptide-intermediate Staphylococcus aureus:: Evaluation of a novel screening method and results of a survey of selected US hospitals [J].

Hubert, SK ;

Mohammed, JM ;

Fridkin, SK ;

Gaynes, RP ;

McGowan, JE ;

Tenover, FC .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3590-3593

[4] Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates [J].

Hussain, FM ;

Boyle-Vavra, S ;

Shete, PB ;

Daum, RS .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (05) :661-667

[5]

Kim HB, 2003, J CLIN MICROBIOL, V41, P2279, DOI [10.1128/JCM.41.6.2279-2281.2003, 10.1128/JCM.41.6.2779-2281.2003]

[6] Laboratory reporting of Staphylococcus aureus with reduced susceptibility to vancomycin in United States Department of Veterans Affairs facilities) [J].

Kralovic, SM ;

Danko, LH ;

Roselle, GA .

EMERGING INFECTIOUS DISEASES, 2002, 8 (04) :402-407

[7] Staphylococcus aureus accessory gene regulator (agr) group II:: Is there a relationship to the development of intermediate-level glycopeptide resistance? [J].

Sakoulas, G ;

Eliopoulos, GM ;

Moellering, RC ;

Novick, RP ;

Venkataraman, L ;

Wennersten, C ;

DeGirolami, PC ;

Schwaber, MJ ;

Gold, HS .

JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (06) :929-938

[8]

Schwaber MJ, 2003, EMERG INFECT DIS, V9, P657

[9] Molecular analysis of coagulase-negative Staphylococcus isolates from blood cultures:: Prevalence of genotypic variation and polyclonal bacteremia [J].

Sharma, M ;

Riederer, K ;

Johnson, LB ;

Khatib, R .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1317-1323

[10] Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo:: Multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S-aureus under the impact of antibiotics administered for chemotherapy [J].

Sieradzki, K ;

Leski, T ;

Dick, J ;

Borio, L ;

Tomasz, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1687-1693

← 1 2 →